2017
Co‐inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma
Lucca LE, Hafler DA. Co‐inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma. Immunological Reviews 2017, 276: 9-25. PMID: 28258696, PMCID: PMC5338636, DOI: 10.1111/imr.12529.Peer-Reviewed Original ResearchConceptsCheckpoint immunotherapyTumor rejectionCommon adult brain tumorsImmune-related side effectsCheckpoint receptor blockadeCo-inhibitory receptorsIntroduction of immunotherapyT cell exhaustionImmune regulatory pathwaysCo-inhibitory pathwaysAdult brain tumorsPrevention of autoimmunityCentral nervous systemAnti-tumor activityDifferent tumor typesCheckpoint inhibitorsReceptor blockadeAdvanced cancerTherapeutic successBrain tumorsSide effectsImmunotherapyNervous systemTherapeutic efficacyTumor types
2008
TIMs: central regulators of immune responses
Hafler DA, Kuchroo V. TIMs: central regulators of immune responses. Journal Of Experimental Medicine 2008, 205: 2699-2701. PMID: 19015312, PMCID: PMC2585854, DOI: 10.1084/jem.20082429.Peer-Reviewed Original ResearchConceptsExhausted T cellsT cell exhaustionHIV infectionPD-1T cellsCell exhaustionMucin domain-containing protein 3Chronic HIV infectionChronic viral infectionsHuman HIV infectionT cell responsesChronic viral diseasesT-cell immunoglobulinDomain-containing protein 3Novel therapeutic targetTim-3Opportunistic infectionsCell immunoglobulinImmune responseTherapeutic targetViral infectionCell responsesProtein 3InfectionViral diseases